Stanton Tam1, Yassir Al-Zubaidi1,2, Md Khalilur Rahman1,3, Kirsi Bourget1,3, Fanfan Zhou3, Michael Murray4,5. 1. Pharmacogenomics and Drug Development Group, Discipline of Pharmacology, School of Medical Sciences, University of Sydney, New South Wales, 2006, Australia. 2. College of Pharmacy, The University of Mashreq, Baghdad, Iraq. 3. Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, New South Wales, 2006, Australia. 4. Pharmacogenomics and Drug Development Group, Discipline of Pharmacology, School of Medical Sciences, University of Sydney, New South Wales, 2006, Australia. michael.murray@sydney.edu.au. 5. Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, New South Wales, 2006, Australia. michael.murray@sydney.edu.au.
Abstract
BACKGROUND: The lack of drug targets is an obstacle to the treatment of patients with triple-negative breast cancer (TNBC). At present, non-specific cytotoxic drugs are first-line agents, but the development of resistance is a major problem with these agents. The epidermal growth factor receptor (EGFR) is a potential target in some TNBCs, because its tyrosine kinase activity drives tumorigenesis. Thus, small molecule inhibitors of the EGFR in combination with cytotoxic agents could be important for the treatment of TNBCs. METHODS: The present study evaluated the efficacies of clinically approved EGFR inhibitors in combination with the cytotoxic agent ixabepilone in parental and docetaxel-resistant MDA-MB-231 cells (231C and TXT cells, respectively). Cell viability was assessed using MTT reduction assays, cell death pathways were evaluated using annexin V/7-aminoactinomycin D staining and flow cytometry and Western immunoblotting was used to assess the expression of pro- and anti-apoptotic proteins in cells. RESULTS: Ixabepilone and the EGFR inhibitors gefitinib and vandetanib inhibited 231C and TXT cell proliferation, but the alternate EGFR inhibitors erlotinib and lapatinib were poorly active. Using combination analysis, ixabepilone/vandetanib was synergistic in both cell types, whereas the ixabepilone/gefitinib combination exhibited antagonism. By flow cytometry, ixabepilone/vandetanib enhanced 231C and TXT cell death over that produced by the single agents and also enhanced caspase-3 cleavage and the pro/anti-apoptotic Bcl-2 protein ratios over ixabepilone alone. CONCLUSIONS: These findings suggest that the ixabepilone/vandetanib combination may have promise for the treatment of patients with drug-resistant TNBC.
BACKGROUND: The lack of drug targets is an obstacle to the treatment of patients with triple-negative breast cancer (TNBC). At present, non-specific cytotoxic drugs are first-line agents, but the development of resistance is a major problem with these agents. The epidermal growth factor receptor (EGFR) is a potential target in some TNBCs, because its tyrosine kinase activity drives tumorigenesis. Thus, small molecule inhibitors of the EGFR in combination with cytotoxic agents could be important for the treatment of TNBCs. METHODS: The present study evaluated the efficacies of clinically approved EGFR inhibitors in combination with the cytotoxic agent ixabepilone in parental and docetaxel-resistant MDA-MB-231 cells (231C and TXT cells, respectively). Cell viability was assessed using MTT reduction assays, cell death pathways were evaluated using annexin V/7-aminoactinomycin D staining and flow cytometry and Western immunoblotting was used to assess the expression of pro- and anti-apoptotic proteins in cells. RESULTS: Ixabepilone and the EGFR inhibitors gefitinib and vandetanib inhibited 231C and TXT cell proliferation, but the alternate EGFR inhibitors erlotinib and lapatinib were poorly active. Using combination analysis, ixabepilone/vandetanib was synergistic in both cell types, whereas the ixabepilone/gefitinib combination exhibited antagonism. By flow cytometry, ixabepilone/vandetanib enhanced 231C and TXT cell death over that produced by the single agents and also enhanced caspase-3 cleavage and the pro/anti-apoptotic Bcl-2 protein ratios over ixabepilone alone. CONCLUSIONS: These findings suggest that the ixabepilone/vandetanib combination may have promise for the treatment of patients with drug-resistant TNBC.
Authors: Galileo A Gonzalez-Conchas; Laura Rodriguez-Romo; David Hernandez-Barajas; Juan F Gonzalez-Guerrero; Ivan A Rodriguez-Fernandez; Adrian Verdines-Perez; Arnoud J Templeton; Alberto Ocana; Bostjan Seruga; Ian F Tannock; Eitan Amir; Francisco E Vera-Badillo Journal: Cancer Treat Rev Date: 2017-10-31 Impact factor: 12.111
Authors: Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Gunter von Minckwitz; Walter Jonat; Peter Fasching; Andreas du Bois; Ulrich Kleeberg; Hans-Joachim Lück; Erika Kettner; Jörn Hilfrich; Wolfgang Eiermann; Julie Torode; Andreas Schneeweiss Journal: Breast Cancer Res Treat Date: 2005-01 Impact factor: 4.872
Authors: José Baselga; Patricia Gómez; Richard Greil; Sofia Braga; Miguel A Climent; Andrew M Wardley; Bella Kaufman; Salomon M Stemmer; António Pêgo; Arlene Chan; Jean-Charles Goeminne; Marie-Pascale Graas; M John Kennedy; Eva Maria Ciruelos Gil; Andreas Schneeweiss; Angela Zubel; Jutta Groos; Helena Melezínková; Ahmad Awada Journal: J Clin Oncol Date: 2013-06-03 Impact factor: 44.544
Authors: Katalin Boér; István Láng; Antonio Llombart-Cussac; Inger Andreasson; Guillermo L Vivanco; Nick Sanders; Gillian M Pover; Elizabeth Murray Journal: Invest New Drugs Date: 2010-09-10 Impact factor: 3.850